Watch Recap of Horizon Day 2026
A pivotal moment in the treatment of chronic disease is here. In real time, we are witnessing the rise of new obesity therapies that have the potential to dramatically change outcomes at scale. At the same time, GLP-1s are being adopted across a healthcare system that’s fragmented and under pressure to keep pace. A gap exists between how well these medications work, and how healthcare systems work to help patients succeed long-term.
At Omada, innovation always starts with our foundational idea: we believe health happens between doctor visits. We believe in closing gaps through care that’s continuous, coordinated and built around a whole person, not a single condition. In order to meet this moment marked by the rise of GLP-1s, we know what that looks like. It calls for several clear-cut product innovations that connect the GLP-1 experience to our proven, whole-person care and provide more flexibility for our customers, including:
- GLP-1 prescribing + between-visit care
- Dedicated support for cholesterol
- Flexible, supportive self-pay options
So what does that new, connected GLP-1 product experience look like?
GLP-1 Prescribing + Between-Visit Care in One Product
Omada is incorporating GLP-1 prescribing and guided medication care directly into the existing member experience, rather than treating GLP-1s as a standalone care pathway. In as little as five minutes, members can schedule and meet with a third-party obesity medicine-trained provider—right from the Omada app—for a comprehensive clinical assessment that includes medical history, mental health screening, readiness for behavior change, and cardiometabolic risk factors.
If members do receive a GLP-1 prescription, they don’t have to go it alone. In a recent survey of over 3,000 GLP-1 patients, we found that most said they want additional support from their provider to help build healthy habits while on GLP-1 treatment, with 68% specifying nutrition guidance and 66% mentioning exercise guidance.That’s why Omada members work with a multi-disciplinary care team on a broader care plan, including nutrition, physical activity, health education, sleep, and stress management support. They also have access to online peer communities comprising other members taking GLP-1s that are facilitated by specially-trained Omada clinical specialists
When a member is prescribed a GLP-1, the rest of the care team activates around them; and this is where connected care comes to life. The provider's visit note and care plan are shared automatically with the member’s health coach and clinical specialists, who start tailoring their support. Everyone on the member’s multi-disciplinary care team occupies a specific role, including care coordination, clinical guidance on medication side effects and adherence, nutrition and exercise support, and more. This integrated approach emphasizes gradual behavior change to drive long-term outcomes and appropriate utilization and cost control measures.
.png?width=1638&height=1025&name=GLP-1%20Prescribing%20(1).png)
New Self-Pay Pathways for Seamless Care
What happens when a benefits strategy doesn’t cover GLP-1s? This reality can’t be ignored, given that patients commonly contend with varied benefits strategies and access issues. Many people who could benefit from GLP-1 therapy still face coverage gaps, formulary exclusions, or high out-of-pocket costs.
But the stakes are high. Research has estimated that over half of U.S. adults could be eligible for semaglutides for either diabetes management, weight loss, or cardiovascular risk prevention. Still, equitable access appears to remain a key obstacle to widespread adoption. In fact, more than 70% of Americans believe GLP-1s are accessible only to higher-income Americans, and just 15% believe they’re accessible to “anyone who needs them”.
In Omada’s survey of non-member GLP-1 patients, 26% of respondents said they pay full out-of-pocket costs; that’s a 5% increase from a similar survey Omada performed in 2024. In response, Omada’s GLP-1 Care Track with Prescribing and Member Cash Pay is designed to create a more streamlined path for self-pay members. “It’s designed for members paying out of pocket,” Shao said. “[It] gives them Omada’s between-visit care and access to their GLP-1 prescription directly through our platform, with options for some of the most affordable cash pay GLP-1 prices on the market.”
Omada’s GLP-1 Care Track with Prescribing and Member Cash Pay wraps evidence-based lifestyle intervention, clinical oversight, and guided medication management around more affordable GLP-1 access options. Cost-sensitive members are not left to navigate medications alone or turn to unsafe, unvetted alternatives. It provides a structured way to address the reality that not all members will have uniform GLP-1 coverage, without abandoning quality or safety, and while supporting responsible use and measurable outcomes.
.png?width=1638&height=1025&name=Dedicated%20Care%20for%20Cholesterol%20(1).png)
Dedicated Care for Cholesterol
High-quality obesity care isn’t just weight loss; it requires looking at the full cardiometabolic picture. More than 60% of people with obesity have elevated cholesterol, often alongside diabetes and hypertension, making cholesterol support essential to addressing cardiometabolic risk. Whatever combination of diabetes, hypertension, or high cholesterol that a member is managing, we treat them together in one connected experience.
Omada for Cholesterol is designed to fit directly into the member experience by addressing cardiometabolic risk factors alongside weight management and GLP-1 therapy. Members receive personalized support grounded in guideline-based lipid management, including guidance on the right dietary changes to impact cholesterol and support for physical activity that can improve HDL and triglyceride levels. For example, members can use simple meal tracking and AI nutrition chats that can take different conditions into account, including high cholesterol, to get instant guidance on heart‑healthy food swaps. Along the way, as is part and parcel of the Omada member experience, online peer communities can provide accountability, encouragement, and ongoing support.
With Omada’s addition of cholesterol support, members taking GLP-1s now get an extra layer of cardiovascular risk mitigation that complements weight loss and diabetes management. Omada care teams can track lipid panels, blood pressure, glycemic markers, and weight together to understand a member’s true risk profile, not just pounds lost.
The Omada model is built around the idea that care should be continuous, coordinated, and centered around members. In other words, we don’t treat conditions, we treat people. That approach is what’s driving our support of 150,000 members we’ve helped navigate GLP-1 journeys so far. In that pursuit, we’ve achieved industry-leading outcomes, including:
- At one year, 67% of GLP-1 members were persistent on their GLP-1 medication, compared to 47-49% in key real-world evidence.1
- At one year, GLP-1 members demonstrated ~2x greater average weight loss than real-world evidence with standard care.
- One year after stopping a GLP-1, Omada members largely maintained their weight, with 63.2% of members maintained or continued to lose weight, and 0.8% average weight change overall.
- In a recent study, Omada members lost 2.1X more body fat, while preserving muscle mass at 12 weeks, compared to control participants.
- In that same study, Omada members reported greater improvements in mental health, physical functioning, and confidence in their ability to lose weight
As GLP-1 adoption drives the next era of obesity and cardiometabolic care for millions of Americans, we aim to support the HR professionals and benefits leaders at the forefront of this paradigm shift. About half of Americans are on employee-sponsored insurance, making it the largest source of health coverage in the U.S. We know that HR professionals and benefits leaders are unrelentingly dedicated to caring for their members. That’s why our mission is to empower them in reshaping how obesity and chronic disease are treated in America and bending the curve of chronic disease.
1. Weight loss outcomes at one year inclusive of time on and off medication
